We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy

Antibody Developability Assessment

Our Approach

Given a candidate antibody sequence, the platform performs developability risk analysis across five dimensions — aggregation, chemical modification, humanness, polyreactivity, and viscosity — and outputs risk assessment results along with quantifiable metrics to support R&D teams in candidate comparison and selection.

Developability Analysis

AggregationChemical ModificationHumannessPolyreactivityViscosity

Why Is This Needed?

"A candidate antibody's developability risk often only surfaces during scale-up or formulation studies — by then, going back to optimize the sequence carries far higher cost and time penalties. Assessing developability early across aggregation, chemical modification, humanness, polyreactivity, and viscosity helps identify potential risks during project selection and sequence design, providing guidance for subsequent experimental design."

Key Advantages

Key Advantages

Traditional Limitations

A Single Metric Is Not Enough

Traditional approaches often focus on a single dimension — such as aggregation or viscosity — and fail to fully capture an antibody's overall development risk.

Manual Assessment Is Slow and Experience-Dependent

Relies on experts manually comparing sequences against reference libraries and scanning modification sites one by one — slow and subject to individual judgment.

Limited Risk-Site Coverage

Focusing on a handful of known risk sites makes it difficult to systematically cover the full range of developability factors.

Our Advantages

Integrated Developability Analysis

Aggregation, chemical modification, humanness, polyreactivity, and viscosity are all delivered at once with risk assessment results and quantitative metrics, comprehensively covering developability risk.

Algorithm-Driven, Fast Batch Processing

Uses analysis metrics such as SEC classification probability, PSR classification probability, DeepViscosity, and OASis to enable fast, batch evaluation of candidate sequences.

AI-Assisted Candidate Comparison

Uses multi-dimensional risk results to assist candidate comparison, helping teams quickly identify priority candidates.

Framework

Developability Analysis

Analyzes antibody candidates systematically based on multi-dimensional features such as sequence, structure, and physicochemical properties, covering five key dimensions: aggregation, chemical modification, humanness, polyreactivity, and viscosity.

Aggregation

Assesses aggregation propensity and colloidal stability in solution, indicating potential risk for high-concentration formulation development.

Analysis Metrics

SEC classification probability, PSH value, SAP developability index

Chemical Modification

Identifies potential chemical liability sites, assessing chemical stability risk during long-term storage and manufacturing.

Analysis Metrics

Potential chemical modification site analysis (e.g. Met oxidation, Asn deamidation, Trp oxidation, etc.)

Humanness

Assesses the similarity of the antibody sequence to a human antibody reference library, reflecting its degree of humanness.

Analysis Metrics

OASis percentile

Polyreactivity

Assesses non-specific binding tendency toward non-target molecules, indicating potential polyreactivity risk.

Analysis Metrics

PSR classification probability, PPC value

Viscosity

Assesses viscosity behavior at high concentration, indicating potential risk for high-concentration formulation development.

Analysis Metrics

DeepViscosity high-viscosity probability, SFvCSP value, Fv surface charge

Pipeline

Pipeline

After submitting a candidate antibody sequence, the platform first performs structure prediction, then runs parallel scanning and risk grading across five dimensions, ultimately outputting multi-dimensional analysis results, metric details, and an AI-generated summary.

Input Antibody Sequence
Structure Prediction
Five-Dimensional Parallel Scan
Risk Analysis & Metric Calculation
Radar Chart & AI Summary Output

The system first generates a structure from the candidate sequence, then independently calculates quantifiable metrics for each dimension and outputs risk assessment results, ultimately generating a detailed metrics report based on the five-dimensional results.

Use Cases

Use Cases and Deliverables

Best suited for projects with candidate antibody sequences that need systematic developability risk assessment at an early stage.

Best-Fit Scenarios

You have a shortlist of candidates and need to quickly compare developability risk across aggregation, chemical modification, humanness, polyreactivity, and viscosity to prioritize sequencing or expression
After antibody engineering or humanization, you need to check whether candidate sequences introduced new aggregation, chemical modification, or polyreactivity risk

Inputs to Prepare

Antibody sequence

What You Receive

Five-dimensional risk radar report (aggregation / chemical modification / humanness / polyreactivity / viscosity, with risk assessment results)
Quantifiable and traceable metric details for each dimension (e.g. SEC probability, PSH value, OASis percentile, PSR probability, DeepViscosity probability)
An overall recommendation based on the five-dimensional results, supporting rapid screening and candidate prioritization

Which dimensions does the five-dimensional developability assessment cover?

Aggregation, chemical modification, humanness, polyreactivity, and viscosity. These five dimensions cover the major risk factors commonly considered during antibody development, and each dimension includes risk results together with quantifiable and traceable computational metrics.

How is aggregation risk assessed?

Aggregation risk is assessed using metrics such as the SEC classification probability, PSH value, and SAP developability index to evaluate colloidal stability and potential aggregation propensity.

What do chemical modification and viscosity assessments each focus on?

Chemical modification identifies potential chemical liability sites such as Met oxidation, Asn deamidation, and Trp oxidation, assessing stability risk during long-term storage and manufacturing. Viscosity uses the DeepViscosity high-viscosity probability, SFvCSP value, and Fv surface charge to assess viscosity risk at high concentration.

How are humanness and polyreactivity assessed?

Humanness is evaluated using metrics such as the OASis percentile to measure how closely the sequence resembles a human antibody reference library, reflecting its degree of humanness. Polyreactivity is evaluated using metrics such as the PSR classification probability and PPC value to assess potential non-specific binding risk.

Identify Candidate Developability Risk Early

Five-dimensional developability assessment is now open for use. Submit a candidate antibody sequence to quickly get a risk radar report covering aggregation, chemical modification, humanness, polyreactivity, and viscosity.